# Bevacizumab Versus Ranibizumab for Diabetic Retinopathy

> **NCT00545870** · PHASE3 · COMPLETED · sponsor: **Ursula Schmidt-Erfurth, M.D.** · enrollment: 30 (actual)

## Conditions studied

- Diabetic Retinopathy
- Diabetic Macular Edema
- Proliferative Diabetic Retinopathy

## Interventions

- **DRUG:** bevacizumab
- **DRUG:** Ranibizumab

## Key facts

- **NCT ID:** NCT00545870
- **Lead sponsor:** Ursula Schmidt-Erfurth, M.D.
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2013-03
- **Final completion:** 2013-04
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2015-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545870, "Bevacizumab Versus Ranibizumab for Diabetic Retinopathy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00545870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*